Trump signs order to speed review of psychedelics including ibogaine

President Trump signed an executive order directing the administration to speed federal reviews of certain psychedelics, including ibogaine, and the FDA plans to issue priority vouchers and take steps toward U.S. human trials.

President Trump signed an executive order directing his administration to accelerate reviews of certain psychedelic drugs, including ibogaine. The move follows advocacy from veterans' groups and some officials who say the drugs warrant more research for hard-to-treat conditions. Administration leaders have proposed federal funding to support state programs studying psychedelics. The announcement comes amid long-standing safety concerns about ibogaine's effects on the heart. Key details: - The order asks the Department of Health and Human Services to direct at least $50 million to states that have or are developing programs to advance psychedelic research. - The Food and Drug Administration will issue national priority vouchers for three psychedelics next week and is taking steps to clear the way for the first U.S. human trials of ibogaine. - Researchers and public health agencies have noted past concerns about ibogaine's cardiovascular toxicity; past NIH work was discontinued and medical literature has linked the drug to more than 30 deaths. - Veterans and some conservative figures have advocated for expanded research, and some U.S. veterans have sought treatment at clinics outside the United States. Summary: The order increases federal attention to psychedelic research and signals possible acceleration of regulatory review and state-level funding for study programs. The FDA's upcoming vouchers and steps toward U.S. human trials are the next procedural moves. Undetermined at this time.